← All trials
NCT04305002
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 21, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Mar 12, 2020
- Last posted
- Mar 12, 2020
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Center for Neurology, StockholmLead sponsor
- Center for Neurology, StockholmOverall official - principal investigator
- Karolinska InstituteCollaborator
- Center for Neurology, StockholmReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.